REG - Impact Healthcare - Result of AGM

Impact Healthcare REITAnnouncement

21/05/2024 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240521:nRSU3349Pa&default-theme=true

RNS Number : 3349P  Impact Healthcare REIT PLC  21 May 2024

21 May 2024

Impact Healthcare REIT plc

("Impact" or the "Company")

Result of 2024 Annual General Meeting

The Board of Impact Healthcare REIT plc (ticker: IHR), the real estate
investment trust which gives investors exposure to a diversified portfolio of
UK healthcare real estate assets, in particular care homes, announces that at
the Company's 2024 Annual General Meeting held today, all resolutions proposed
at the AGM were voted on and passed by a poll by the Company's shareholders
and the results of the poll, including the proxy votes received, are set out
below.

 

Resolutions 1 to 14 (inclusive) were proposed as ordinary resolutions and
resolutions 15 to 18 (inclusive) were proposed as special resolutions.

 

     Resolution                                                                    Votes For*   %        Votes Against  %      Total votes validly cast  Total votes cast as % of issued share capital  Votes Withheld **
 1   Receive the Annual Report and Financial Statements Year 31 December 2023      253,990,339  98.07%   5,000,000      1.93%  258,990,339               62.50%                                         454,356
 2   Approve the directors' remuneration policy                                    259,266,401  99.98%   62,982         0.02%  259,329,383               62.58%                                         115,312
 3   Approve the directors' remuneration report                                    259,268,331  99.98%   61,052         0.02%  259,329,383               62.58%                                         115,312
 4   Approve the Company's Dividend Policy                                         259,439,371  100.00%  0              0.00%  259,439,371               62.61%                                         5,324
 5   Re-elect Simon Laffin as a director                                           253,685,324  99.99%   18,692         0.01%  253,704,016               61.23%                                         5,740,679
 6   Re-elect Rosemary Boot a director                                             259,323,378  99.95%   120,965        0.05%  259,444,343               62.61%                                         352
 7   Re-elect Amanda Aldridge as a director                                        256,397,863  98.83%   3,046,479      1.17%  259,444,342               62.61%                                         353
 8   Re-elect Chris Santer as a director                                           259,419,355  99.99%   24,988         0.01%  259,444,343               62.61%                                         352
 9   Elect Cedi Frederick as a director                                            259,427,432  99.99%   16,911         0.01%  259,444,343               62.61%                                         352
 10  To re-appoint BDO LLP as the Company's auditor                                254,409,647  99.99%   26,900         0.01%  254,436,547               61.40%                                         5,008,148
 11  To authorise the board of directors to determine the auditors remuneration    259,431,918  100.00%  8,629          0.00%  259,440,547               62.61%                                         4,148
 12  To authorise the continuation of the Company                                  259,434,033  100.00%  1,810          0.00%  259,435,843               62.61%                                         8,852
 13  To authorise the Directors to allot shares under section 551 Companies Act    259,375,339  99.98%   49,328         0.02%  259,424,667               62.61%                                         20,028
     2006
 14  Subject to the passing of resolution 11, to authorise the Directors to allot  254,376,269  98.05%   5,048,398      1.95%  259,424,667               62.61%                                         20,028
     additional shares under section 551 Companies Act 2006
 15  Subject to the passing of resolution 12, to disapply statutory pre-emption    240,489,252  92.70%   18,935,415     7.30%  259,424,667               62.61%                                         20,028
     rights under section 570 Companies Act 2006
 16  Subject to the passing of resolution 13, to disapply statutory pre-emption    240,265,205  92.61%   19,167,961     7.39%  259,433,166               62.61%                                         11,529
     rights under section 570 Companies Act 2006
 17  To authorise the Company to make market purchase of its own ordinary shares   252,974,475  97.52%   6,427,561      2.48%  259,402,036               62.60%                                         42,659
 18  To permit general meetings to be called on 14 days' notice                    254,380,724  98.05%   5,063,617      1.95%  259,444,341               62.61%                                         354

 

Every shareholder has one vote for every Ordinary Share held. As at close of
business on 17 May 2024, the share capital of the Company consisted of
414,368,169 Ordinary Shares with voting rights. The Company does not hold any
shares in Treasury.

 

In accordance with Listing Rule 9.6.2, copies of all the resolutions passed,
other than ordinary business, will be submitted to the National Storage
Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

* Includes discretionary votes.

** A vote withheld is not a vote in law and is not counted in the calculation
of the votes for or against a resolution.

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

 Impact Health Partners LLP                    via Maitland/AMO

 Andrew Cowley

 JTC (UK) Limited - Company Secretary          0207 409 0181

 Christopher Gibbons                           Impact.CoSec@jtcgroup.com (mailto:Impact.CoSec@jtcgroup.com)

 H/Advisors Maitland (Communications advisor)  07747 113 930

 James Benjamin                                impacthealth-maitland@h-advisors.global
                                               (mailto:impacthealth-maitland@h-advisors.global)

 

The Company's LEI is 213800AX3FHPMJL4IJ53.

 

NOTES:

Impact Healthcare REIT plc acquires, renovates, extends and redevelops high
quality healthcare real estate assets in the UK and lets these assets on
long-term full repairing and insuring leases to high-quality established
healthcare operators which offer good quality care, under leases which provide
the Company with attractive levels of rent cover.

The Company aims to provide shareholders with an attractive sustainable
return, principally in the form of quarterly income distributions and with the
potential for capital and income growth, through exposure to a diversified and
resilient portfolio of UK healthcare real estate assets, in particular care
homes for the elderly.

The Company's dividend policy is to maintain a progressive dividend that is
covered by adjusted earnings.

On this basis, the target total dividend for the year ending 31 December 2024
is 6.95 pence per share(*), a 0.18 pence increase over the 6.77 pence in
dividends paid or declared per ordinary share for the year ended 31 December
2023.

The Group's Ordinary Shares trade on the main market of the London Stock
Exchange, premium segment. The Company is a constituent of the FTSE
EPRA/NAREIT index.

*     This is a target only and not a profit forecast. There can be no
assurance that the target will be met and it should not be taken as an
indicator of the Company's expected or actual results.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGABMITMTMTBII